Rna Interference (Rnai) Therapies For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Treatment Name | RNA Interference (RNAi) Therapies |
|---|---|
| Category | Gene Silencing Therapies |
| Mechanism | Double-stranded RNA molecules that induce sequence-specific mRNA degradation |
| Delivery | Lipid nanoparticles, AAV vectors, GalNAc conjugates |
| Diseases | Huntington's Disease, Alzheimer's Disease, Parkinson's Disease, ALS |
| Status | Clinical Trials (HD, AD), FDA Approved (transthyretin amyloidosis) |
RNA interference (RNAi) therapies utilize the body's natural cellular machinery to selectively silence disease-causing genes. RNAi is a biological process where double-stranded RNA molecules trigger the degradation of specific messenger RNA (mRNA) sequences, preventing translation into disease-relevant proteins[1]. This approach has shown tremendous promise for neurodegenerative diseases where genetic mutations cause toxic protein accumulation.
RNAi leverages endogenous cellular machinery[2]:
| Molecule | Length | Origin | Key Features |
|---|---|---|---|
| siRNA | 21-23 bp | Synthetic | Direct RISC loading, transient effect |
| shRNA | 50-70 bp | Vector-encoded | Processed by Dicer, can be long-lasting |
| miRNA mimics | ~22 bp | Synthetic | Partial complementarity, translational repression |
Note: These are for peripheral amyloidosis but demonstrate CNS delivery potential
| Vector | Advantages | Limitations |
|---|---|---|
| AAV | Long-term expression, broad CNS tropism | Limited cargo capacity (~4.7 kb) |
| LV | Larger cargo, integration options | Safety concerns |
| Adeno-associated | Safety, long-term expression | Immune response |
| Method | Application | Advantages |
|---|---|---|
| Lipid nanoparticles (LNPs) | siRNA delivery | Well-tolerated, scalable |
| GalNAc conjugates | Liver targeting | Subcutaneous delivery |
| Exosomes | CNS targeting | Endogenous, low immunogenicity |
| Focused ultrasound | BBB opening | Non-invasive |
| Feature | RNAi | ASO | CRISPR |
|---|---|---|---|
| Mechanism | mRNA degradation | Multiple | DNA editing |
| Permanence | Transient | Transient | Permanent |
| Delivery | Viral/non-viral | Synthetic | Viral |
| Cost | High | High | Very high |
| Drug | Company | Target | Disease | Phase |
|---|---|---|---|---|
| ALN-APP | Alnylam | APP | AD | Phase 1 |
| Vutrisiran | Alnylam | TTR | ATTR | Approved |
| RO-7246574 | Roche | SOD1 | ALS | Phase 1 |
The study of Rna Interference (Rnai) Therapies For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Fire A, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806-811. PMID:9486653 ↩︎
Dykxhoorn DM, et al. Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol. 2003;4(6):457-467. PMID:12778125 ↩︎